Coastar Therapeutics

Executive Summary

Coastar Therapeutics is a preclinical-stage biotechnology company developing a novel erythrocyte-derived membrane (EDM) gene delivery platform to overcome key challenges in genetic medicine, including immune clearance and lack of tissue targeting. Founded in 2021 and headquartered in San Diego, the company's technology leverages red blood cell membranes to encapsulate nucleic acid therapeutics, potentially enabling repeat dosing without immune neutralization and allowing precise delivery to target cells. Coastar aims to address the high unmet need in genetic diseases where existing viral and non-viral vectors face limitations. While the company is still in early development and has not publicly disclosed specific pipeline programs or funding amounts, its EDM platform offers a differentiated approach in the competitive gene therapy landscape. The success of Coastar hinges on in vivo proof-of-concept studies and securing partnerships or financing to advance toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data in genetic disease model40% success
• Q2 2027Series A financing or strategic partnership55% success
• Q1 2028IND-enabling studies initiation30% success